Navigation Links
Osteoporosis to Be Detected During Routine Dental X-rays

ental radiographs, dentists can predict the osteoporotic condition of the patients to the same extent as the BMD measurements.

The image analysis can be automated and does not require extra time on the part of the dentist. The newly developed technique means that patients who are identified as being at risk can be referred for more thorough appropriate examinations.

Source-Eurekalert
PR
'"/>




Page: 1 2

Related medicine news :

1. New treatment for Osteoporosis
2. Osteoporosis in men
3. Osteoporosis Drugs: right time to take-off
4. Fluoride Found Effective in Osteoporosis
5. Mutation connected to Osteoporosis
6. Osteoporosis associated with Childhood Cancer
7. A treatment for Osteoporosis
8. Osteoporosis could be caused by irregular periods
9. Back exercises reduces Osteoporosis
10. Osteoporosis and kidney stones gene marker identified
11. The Answer To Prevent Osteoporosis
Post Your Comments:
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...Marriage guidance counseling sessions are sometime... blame and slow to accept responsibility for a rel...ouples report progress, the others say counseling ...hed positions. An Australian psychologist is expe...
...PASADENA, Calif., June 6 /PRNewswire-USNewswire/ -...e and monitor treatments for hardening of the arte...attacks and strokes. Hospitals and doctors around... software initially developed at NASA's Jet Propul...
...A solar torch, homemade compost machine, jute bags...made from poly packs, salt-rock lamps and many mo...el here to spread awareness about a cleaner future...i to think in terms of environment and make Delhi ...
...RARITAN, N.J., Johnson & Johnson Pharmaceutical Re...hat it has submitted a New Drug Application (NDA) ...(FDA) for doripenem, an investigational carbapene...socomial pneumonia, a pneumonia that is acquired i...
Other Medicine News:Health News:NASA Technology Helps Detect and Treat Heart Disease and Strokes 2Health News:NASA Technology Helps Detect and Treat Heart Disease and Strokes 3Health News:A Welcome Initiative to Spread Awareness on Environment 2
(Date:9/3/2008)...ease Awareness Month, CHARLOTTESVILLE, Va., Sept....a clinical-stage drug-development company commerci...al needs, announced today that it has begun,to enr... lead drug,candidate trans sodium crocetinate (TSC...altrials.gov Website, is investigating TSC as a tr...
(Date:9/3/2008)...- Panacea Pharmaceuticals,Inc. today announced th...g,antibodies against human aspartyl (asparaginyl) ...r biomarker and therapeutic target. These antibodi...husetts Institute of,Technology (MIT) and Panacea ... development of human cancer diagnostics and thera...
(Date:9/3/2008)...lans with FDA, PRINCETON, N.J., Sept. 3 /PRNewswi...hat it successfully completed two key clinical tri...ative low-dose, once-weekly,contraceptive patch, ...t,code AG-200-15. The Phase 2b safety and efficacy...ulation suppression, cycle control and safety. The...
(Date:9/3/2008)...nce Pycnogenol(R) Lowers Joint, Pain, Symptoms; Ma...ation of the Extract, ...to the Center for,Disease Control (CDC), osteoarth...e rise. A new study published in the August journa... bark extract from the French maritime pine,tree, ...
Breaking Medicine Technology:Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Romark Laboratories Completes Enrollment in U S Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non Responders 2156 1Romark Laboratories Completes Enrollment in U S Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non Responders 2156 2Romark Laboratories Completes Enrollment in U S Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non Responders 2156 3Iraq war service 3A A risk factor for bronchiolitis 3F 19967 1Iraq war service 3A A risk factor for bronchiolitis 3F 19967 2Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 1Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 2Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 3Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 4Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 5New Anticoagulation Management Software Helps Clinics Enhance Efficiency and Improve Patient Safety 19962 1New Anticoagulation Management Software Helps Clinics Enhance Efficiency and Improve Patient Safety 19962 2
... WIRE)--May 1, 2007 - Teva,Pharmaceutical Industri... data from a 36-week, randomized, double-blind,pl... an oral 0.6 mg,dose of laquinimod given daily sig...) disease activity by 38 percent in RRMS,patients ...avorable,trend towards reducing annual relapse rat...
...isease Activity as Measured,by MRI and Relapse --...nc.,(NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BII...inical study of Rituxan®,(rituximab) in patien...MS) were presented today at the American Academy o... is a therapeutic antibody,that targets and select...
Other Medicine Technology:Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 2Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 3Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 4Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 5Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 6Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 2Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 3Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 4Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 5Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 6
...ic stools come with five legs for extra stability....ical travel 6"). 2" ball bearing swivel hard rubbe... upholstery, available in black vinyl as standard,... a contoured, padded, upholstered backrest, with v...
Anterior Stromal Puncture Cannula, 25 g. For treatment of recurrent corneal erosion. Overall length 24 mm. 5/box.
Viscoelastic Cannula, 27 g. Angled. 7 mm angled tip cannula with unique hub that facilitates flow of viscoelastic material. Overall length 23 mm. 5/box.
Anterior Chamber Needle, 30 g. Angled. 5 mm angled tip. Overall length 20 mm. 5/box.
Medicine Products: